663 related items for PubMed ID: 27558467
1. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T.
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[Abstract] [Full Text] [Related]
2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K.
BMC Nephrol; 2018 Nov 01; 19(1):302. PubMed ID: 30382824
[Abstract] [Full Text] [Related]
3. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S.
Pediatr Nephrol; 2016 Jan 01; 31(1):89-95. PubMed ID: 26341251
[Abstract] [Full Text] [Related]
4. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
Hogan J, Dossier C, Kwon T, Macher MA, Maisin A, Couderc A, Niel O, Baudouin V, Deschênes G.
Pediatr Nephrol; 2019 Feb 01; 34(2):253-259. PubMed ID: 30109447
[Abstract] [Full Text] [Related]
5. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.
Fujinaga S, Sakuraya K, Yamada A, Urushihara Y, Ohtomo Y, Shimizu T.
Pediatr Nephrol; 2015 Apr 01; 30(4):687-91. PubMed ID: 25576066
[Abstract] [Full Text] [Related]
6. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K.
Pediatr Nephrol; 2013 Feb 01; 28(2):257-64. PubMed ID: 23052656
[Abstract] [Full Text] [Related]
7. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K, Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
Pediatr Nephrol; 2017 Nov 01; 32(11):2071-2078. PubMed ID: 28664242
[Abstract] [Full Text] [Related]
8. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
Fujinaga S, Hirano D, Nishino T, Umeda C, Watanabe Y, Nakagawa M.
Pediatr Nephrol; 2019 Nov 01; 34(11):2417-2421. PubMed ID: 31435725
[Abstract] [Full Text] [Related]
9. Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.
Ohyama R, Fujinaga S, Sakuraya K, Hirano D, Ito S.
Clin Exp Nephrol; 2023 Oct 01; 27(10):865-872. PubMed ID: 37477752
[Abstract] [Full Text] [Related]
10. Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis.
Suyama K, Kawasaki Y, Miyazaki K, Kanno S, Ono A, Suzuki Y, Ohara S, Hosoya M.
Pediatr Int; 2016 Mar 01; 58(3):219-223. PubMed ID: 26275234
[Abstract] [Full Text] [Related]
11. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K, Japanese Study Group of Kidney Disease in Children.
J Am Soc Nephrol; 2022 Feb 01; 33(2):401-419. PubMed ID: 34880074
[Abstract] [Full Text] [Related]
12. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
Lancet; 2014 Oct 04; 384(9950):1273-81. PubMed ID: 24965823
[Abstract] [Full Text] [Related]
13. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T.
Nephrol Dial Transplant; 2012 Mar 04; 27(3):1083-9. PubMed ID: 21810762
[Abstract] [Full Text] [Related]
14. Novel use of rituximab for steroid-dependent nephrotic syndrome in children.
Kimata T, Hasui M, Kino J, Kitao T, Yamanouchi S, Tsuji S, Kaneko K.
Am J Nephrol; 2013 Mar 04; 38(6):483-8. PubMed ID: 24296765
[Abstract] [Full Text] [Related]
15. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
Basu B, Babu BG, Mahapatra TK.
Clin Exp Nephrol; 2017 Feb 04; 21(1):143-151. PubMed ID: 27108294
[Abstract] [Full Text] [Related]
16. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F.
Pediatr Nephrol; 2008 Aug 04; 23(8):1269-79. PubMed ID: 18465150
[Abstract] [Full Text] [Related]
17. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.
Fujinaga S, Nishino T, Umeda C, Tomii Y, Watanabe Y, Sakuraya K.
Pediatr Nephrol; 2019 Feb 04; 34(2):353-357. PubMed ID: 30426219
[Abstract] [Full Text] [Related]
18. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome.
Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T.
Clin Nephrol; 2016 Jun 04; 85(6):340-5. PubMed ID: 27125626
[Abstract] [Full Text] [Related]
19. Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.
Maxted AP, Dalrymple RA, Chisholm D, McColl J, Tse Y, Christian MT, Reynolds BC.
Pediatr Nephrol; 2019 May 04; 34(5):855-863. PubMed ID: 30564878
[Abstract] [Full Text] [Related]
20. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K.
Pediatr Nephrol; 2011 Oct 04; 26(10):1823-8. PubMed ID: 21556716
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
